Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

 Bardet-Biedl Syndrome / Posted 1 year ago

The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight, hunger assessments and other factors in patients with rare genetic disorders of obesity, including POMC deficiency, LepR deficiency, Bardet-Biedl syndrome and Alström syndrome.

  • Study start date : 01/01/2017
  • Study end date : 01/05/2021
  • Wales-Based Study Contact : please speak to your clinician
Contact details

Hammersmith Hospital London W12 0HS Queen Elizabeth Hospital Birmingham B152TH Addenbrooke's Hospital Cambridge CA2 0QQEngland

No post found